Lukas Ruoff

Mr. Lukas Ruoff

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRoxana Moayedifar
Roxana Moayedifar
MCMuhammed Ilkay Celik
Muhammed Ilkay Celik
BKBarbara Karner
Barbara Karner
ASAnne-Kristin Schaefer
Anne-Kristin Schaefer
HAHebe Al Asadi
Hebe Al Asadi
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
Background/Objectives: Preoperative hypoalbuminemia is a known risk factor for adverse outcomes in cardiac surgery, but its role in patients undergoing HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation is unclear. This study evaluated the association between albumin levels and postoperative outcomes, aiming to define a clinically meaningful cut-off for risk stratification. Methods: We retrospectively analyzed 205 adult patients who underwent HM3 implantation at a single center from June 2014 to December 2023. Receiver operating characteristic (ROC) analysis identified an optimal pre-implant albumin cut-off of <32 g/L. This threshold, derived using the maximal Youden Index, provided a sensitivity of 52.1%, specificity of 71.6%, and an AUC of 0.64 (95% CI 0.56–0.71), with internal bootstrapping validation confirming model stability, and calibration demonstrating good agreement between predicted and observed outcomes. Kaplan–Meier analysis assessed freedom from hemocompatibility-related adverse events (HRAEs) and survival. Cox proportional hazards models evaluated albumin and other variables as independent risk factors for HRAEs. Results: Patients with pre-implant albumin <32 g/L had higher rates of HRAEs, including stroke (24.9% vs. 8.4%, p = 0.004) and bleeding (38.1% vs. 23.2%, p = 0.012). Freedom from HRAEs was significantly lower in the hypoalbuminemia group (45.2% vs. 69.8%, p < 0.001) and competing risk-adjusted cumulative incidence for HRAE was higher, but did not reach statistical significance (p = 0.11), one-year HRAE-free survival was also reduced (68.5% vs. 85.7%, p = 0.03). In multivariable analysis, low albumin (HR 0.56, 95% CI 0.33–0.93, p = 0.026) and temporary right ventricular assist device (RVAD) support (HR 3.32, 95% CI 2.05–5.39, p < 0.001) were independent predictors of HRAEs. Conclusions: Low preoperative albumin is independently associated with increased HRAEs and reduced one-year survival after HM3 implantation. Compared with the traditional 35 g/L threshold, the ROC-derived 32 g/L cut-off offered superior balance between sensitivity and specificity, underscoring its clinical utility. Albumin may serve as a simple, pragmatic, and cost-effective biomarker for preoperative risk assessment and optimization.

8 September 2025 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
LRLukas Ruoff
Lukas Ruoff
GWGregor Widhalm
Gregor Widhalm
MRMichael Röhrich
Michael Röhrich
HAHebe Al Asadi
Hebe Al Asadi
LCLuca Conci
Luca Conci
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
Aims: Despite the excellent clinical outcomes of the HeartMate 3 (HM3) left ventricular assist device, the current pump monitoring limits in-depth pump data analysis. This study investigated HM3 pump parameters collected non-invasively with HM3 Snoopy during orthostatic transitions (OTs). Methods and results: In this single-centre cohort study, a standardized OT protocol was developed, involving postural changes between supine, seated, and standing. Data were recorded using the HM3 Snoopy and a Holter electrocardiogram. Pump flows (QMIN, QMEAN, QMAX), pulsatility index (PI), pump speed, MagLev parameters, and heart rate were synchronized per second. The primary outcome was the identification of distinct orthostatic pump flow response phenotypes. Further, a binary classifier using MagLev parameters, to differentiate between supine and upright patient positions, was developed and assessed. In 25 HM3 patients (age: 61.2 ± 9.6 years, female: 12%, body mass index: 26.8 ± 4.7 kg/m2), greater flow alterations were observed during transitions from supine to standing vs. seated to standing, with most significant changes in QMIN [3 (-13; 10)%]. Phenotypes were identified across 75 OTs as no flow response (60%), undesired unloading with a loss in QMIN ≥ 50% (20%), and loss of pulsatility ≥ 50% (16%). The MagLev patient position classifier achieved a median sensitivity of 88% and specificity of 86% across the entire cohort. Conclusion: Three HM3 pump flow response phenotypes were identified in response to OTs, challenging the utilization of PI events to detect undesired unloading events. A MagLev-based position classifier revealed potential for differentiation of HM3 patient position.

17 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JRJulia Riebandt
Julia Riebandt
RMRoxana Moayedifar
Roxana Moayedifar
LRLukas Ruoff
Lukas Ruoff
HAHebe Al Asadi
Hebe Al Asadi
SSSanja Jana Söllner
Sanja Jana Söllner
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
Objectives: The Impella 5.5 (J&J MedTech, USA) is increasingly used for refractory cardiogenic shock (CS), yet early predictors of mortality and recovery remain unclear. This study aimed to evaluate early patient characteristics and device-related parameters in relation to clinical outcomes; to compare outcome-based phenotypic groups (native heart recovery (NHR), heart replacement therapy (HRT), and death on the device (DEC)); and to analyze P-level impact on hemolysis and acute kidney injury. Methods: This retrospective single-center study included 28 CS patients supported with Impella 5.5 between May 2023 and August 2024. Data included intensive care unit (ICU) hemodynamics, vasoactive-inotropic score (VIS), lab markers, and pump parameters. Primary analysis evaluated early (first 24 h) parameters as potential indicators associated with mortality on the device and recovery, while secondary analyses compared hemodynamic and pump performance parameters across outcome groups, evaluated the association between P-level and hemolysis, and assessed the impact of shock etiology on clinical outcomes. Results: Among 28 patients (mean age 56 years, 10.7% female, body mass index (BMI) 27.7 kg/m2), NHR occurred in 39.3% and bridged to HRT in 42.9%. Non-survivors (17.8%) had significantly higher lactate (3.1 vs. NHR: 1.9 vs. HRT: 1.4 mmol/L, p < 0.001) and VIS (307.0 vs. NHR: 18.8 vs. HRT: 12.6, p < 0.001) at implantation. Higher VIS values (>69) were strongly associated with mortality on the device, with 100% sensitivity and 77% specificity (area under the curve (AUC) = 0.86); VIS < 9.9 was related to NHR (AUC = 0.63, 94% sensitivity, 45% specificity). P-levels were not linked to hemolysis index (r = −0.03, p = 0.64) or lactate dehydrogenase (r = −0.06, p = 0.37). Conclusions: Early vasoactive burden was associated with clinical outcomes in Impella 5.5-supported patients. No association between P-levels and the analyzed hemolysis surrogates was detected in this cohort. Distinct phenotypes across recovery outcomes may guide personalized management, but prospective validation of this exploratory and hypothesis-generating analysis is needed.